Electronic Acknowledgement Receipt					
EFS ID:	1118374				
Application Number:	10748484				
Confirmation Number:	9463				
Title of Invention:	ANTIBODY TO MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10				
First Named Inventor:	Darrell C. Conklin				
Correspondence Address:	Shelby J. Walker Patent Department ZymoGenetics, Inc. 1201 Eastlake Avenue East Seattle WA 98102 US 2064426600				
Filer:	Shelby J. Walker./Linda Povinelli				
Filer Authorized By:	Shelby J. Walker.				
Attorney Docket Number:	97-72D1				
Receipt Date:	18-JUL-2006				
Filing Date:	29-DEC-2003				
Time Stamp:	21:09:04				
Application Type:	Utility				
International Application Number:					
Payment information:					

Payment information:

Submitted with Payment	no	
------------------------	----	--

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Issue Fee Payment Recorded	97-72D1IssueFeeTransmittal .pdf	72169	no	1
Warnings:					
Information					
		Total Files Size (in bytes):	72169		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.